Maze Therapeutics, Inc. (MAZE) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.44B USD. 52-week range 21.95 to 53.65 USD. Data as of 2026-10-09.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of ...